Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Recruiting now

Conditions studied: Mycosis Fungoides, Sezary Syndrome

In brief

The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.

Key facts

Study ID: NCT07132567
Run by: Kyowa Kirin Co., Ltd.
People needed: 15
Starts: 2025-05-02
Expected to finish: 2028-11-01
Last updated by the study team: 2025-09-22

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adults 19 years of age or older
Individuals who are confirmed to have received administration of the study drug for the purpose of "the treatment for adult patients with fungoidal granuloma or Sezary syndrome who have received one or more systemic therapies," or who are considered to require administration of the study drug in the investigator's opinion
Individuals who (or whose legally acceptable representatives) signed the Consent to Use of Personal Information of their own free will for participation in this use-result surveillance

You may not qualify if…

Patients with hypersensitivity to any ingredients of this drug
Patients who intend to use this drug for non-approved indications
Patients who participated in a pre-market clinical trial of the study drug and received administration of the study drug

Where it is running

Kosin University Gospel Hospital — Busan, Busan Metropolitan City, South Korea (enrolling)
Ewha Womans University Mokdong Hospital — Seoul, South Korea (enrolling)
Samsung Medical Center — Seoul, South Korea (enrolling)
Seoul National University Hospital — Seoul, South Korea (enrolling)
Seoul National University Hospital — Seoul, South Korea (enrolling)
Chung-Ang University Hospital — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.